People In Brief
This article was originally published in The Gray Sheet
Executive Summary
NovoStent gets new CEO: Ray Martin, PhD, will replace the firm's founder and primary inventor, Michael Hogendijk, as President & CEO. Hogendijk will continue as chief technical officer. Martin was most recently VP-business development of TriVascular, which was acquired by Boston Scientific in April. He also has held executive positions at Bard and W.L. Gore, where he co-invented the Gore Viabahn and Hemobahn stent grafts. NovoStent recently raised $3.1 mil. for its first human trial evaluating its self-expanding helical stent in the superficial femoral artery, scheduled to start in 2006 (1"The Gray Sheet" Sept. 5, 2005, p. 14)...